HER2-Targeted Multifunctional Silica Nanoparticles Specifically Enhance the Radiosensitivity of HER2-Overexpressing Breast Cancer Cells
Open accessThe DOI matches its Crossref record; 40 of the 43 references it cites were found in a registry or an index.
Abstract
We investigated the effects of targeted functionalized silica nanoparticles on the radiosensitivity of cancer cells. Better control of the local concentration of silica nanoparticles may facilitate their use as an adjuvant in conjunction with ionizing radiation to target cancer cells while preventing damage to normal cells. Hyperbranched polyamidoamine (PAMAM) was grafted onto the surface of amorphous silica nanoparticles to functionalize them. The PAMAM-coated silica nanoparticles (PCSNs) were then conjugated with fluorescent dyes. Anti-HER2 antibodies were covalently attached to the labeled PCSNs. The HER2-overexpressing SK-BR3 breast cancer cell line was incubated in medium containing the PCSN probes. After incubation; the cells were exposed to X-ray radiation. Cells were counted in all samples using cell proliferation assays; and apoptotic cells were detected. The cell survival results showed that the combination of the targeted PCSN probes and radiation reduced the survival rate of SK-BR3 cells to a greater extent than when either PCSN probes, PCSNs or radiation were applied individually. The results also showed an increase in apoptosis in the SK-BR3 cells that internalized the PCSN probes and were then irradiated. Based on these data, PCSN probes act as specific radiosensitizing agents for HER2-overexpressing cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures













Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A high degree of functionalization was reported across studies. Many nanoplatforms incorporated targeting ligands, therapeutic payloads, and microenvironment-responsive components [16,17,26,27,45,49,51,52,53].”
From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [51]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Receptor-specific targeting approaches, including HER2-, CXCR4-, and folate-directed systems, were described in association with increased cellular uptake [20,24,29,51,54,55].”
From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [51]
The cited source says what the claim attributes to it.
In the citing paper
“Receptor-specific targeting, including HER2-, CXCR4-, and folate-directed systems, was frequently described and associated with increased cellular uptake [20,24,29,49,51,55,70].”
From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
Stockwell, B. R., Friedmann Angeli, J. P., Bayir, H., Bush, A. I., Conrad, M., Dixon, S. J., Fulda, S., Gascón, S., Hatzios, S. K., Kagan, V. E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.021 · Cited by 7,695
Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity
Stern, S. T., Adiseshaiah, P. P., & Crist, R. M. (2012) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-9-20 · Cited by 836
The lysosome: from waste bag to potential therapeutic target
Appelqvist, H., Wäster, P., Kågedal, K., & Öllinger, K. (2013) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjt022 · Cited by 772
Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma
Benezra, M., Penate-Medina, O., Zanzonico, P. B., Schaer, D., Ow, H., Burns, A., DeStanchina, E., Longo, V., Herz, E., Iyer, S., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45600 · Cited by 645 · cited 2×
“Furthermore, diagnostic probes composed of silica nanoparticles have already been approved for phase 1 human clinical trials, and the first clinical trial investigating modified fluorescent core-shell silica nanoparticles is in progress [13,14].”
BackgroundSalinomycin kills cancer stem cells by sequestering iron in lysosomes
Mai, T. T., Hamaï, A., Hienzsch, A., Cañeque, T., Müller, S., Wicinski, J., Cabaud, O., Leroy, C., David, A., Acevedo, V., et al. (2017) · Nature Chemistry · doi:10.1038/nchem.2778 · Cited by 612
Size‐Dependent Cytotoxicity of Monodisperse Silica Nanoparticles in Human Endothelial Cells
Napierska, D., Thomassen, L. C. J., Rabolli, V., Lison, D., Gonzalez, L., Kirsch‐Volders, M., Martens, J. A., & Hoet, P. H. (2009) · Small · doi:10.1002/smll.200800461 · Cited by 585 · cited 1×
“Generally, small silica nanoparticles exert greater effects than larger nanoparticles [20,23].”
BackgroundIn search of breast cancer culprits: suspecting the suspected and the unsuspected.
Subik, K., Lee, J.-F., Baxter, L., Strzepek, T., Costello, D., Crowley, P., Xing, L., Hung, M., Bonfiglio, T. A., Hicks, D. G., et al. (2008) · PubMed Central · Cited by 577
Subik, K., Lee, J.-F., Baxter, L., Strzepek, T., Costello, D., Crowley, P., Xing, L., Hung, M.-C., Bonfiglio, T., Hicks, D. G., et al. (2010) · Breast Cancer: Basic and Clinical Research · doi:10.1177/117822341000400004 · Cited by 573 · cited 1×
“The human breast cancer cell line SK-BR3 (HER2; 3+) [7] was obtained from the American Type Culture Collection (ATCC® number HTB-30TM).”
MethodChang, J.-S., Chang, K. L. B., Hwang, D.-F., & Kong, Z.-L. (2007) · Environmental Science & Technology · doi:10.1021/es062347t · Cited by 403 · cited 1×
“Moreover, a study comparing the cell damage caused by SiO2 nanoparticles revealed that there was no significant difference between 15-nm and 46-nm particles, and the cell damage they caused was dependent on the concentration and time [24].”
BackgroundKlapper, L. N., Waterman, H., Sela, M., & Yarden, Y. (2000) · PubMed · Cited by 351
Cited by
Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?
Vallet-Regí, M., Schüth, F., Lozano, D., Colilla, M., & Manzano, M. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00659b · Cited by 507
Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: An update
Castillo, R. R., Lozano, D., González, B., Manzano, M., Izquierdo-Barba, I., & Vallet-Regí, M. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1598375 · Cited by 197
“MSNs: sensitizing agent for radiotherapy [43].”
Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment
Isa, E. D. M., Ahmad, H., Rahman, M. B. A., & Gill, M. R. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020152 · Cited by 150
Gisbert-Garzarán, M., & Vallet‐Regí, M. (2020) · Nanomaterials · doi:10.3390/nano10050916 · Cited by 89
Mesoporous silica nanoparticles as a versatile nanocarrier for cancer treatment: A review
Taleghani, A. S., Nakhjiri, A. T., Khakzad, M. J., Rezayat, S. M., Ebrahimnejad, P., Heydarinasab, A., Akbarzadeh, A., & Marjani, A. (2021) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2021.115417 · Cited by 79
Recent Advances in Mesoporous Silica Nanoparticle-Mediated Drug Delivery for Breast Cancer Treatment
Rani, R., Malik, P., Dhania, S., & Mukherjee, T. K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010227 · Cited by 66
“As the PCSN probes were first internalized and then irradiated by X-rays, they could be considered as localized sensitization-mediated outcomes in HER2-overexpressing BC cells [175].”
BackgroundBilynsky, C., Millot, N., & Papa, A. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10256 · Cited by 52
“Silica NPs functionalized with hyperbranched polyamidoamine as well as an anti-HER2 antibody successfully targeted human SK-BR-3 breast cancer cells overexpressing HER2.(99) HER2 is a rational target beyond just breast cancer, as multiple epithelial tumor types correlate HER2 overexpression with poor clinical outcome.”
BackgroundMesoporous Silica Nanoparticles for Targeting Subcellular Organelles
Gisbert-Garzarán, M., Lozano, D., & Vallet‐Regí, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249696 · Cited by 53
“In this regard, MSNs have been modified with FDA-approved monoclonal antibodies such as Trastuzumab (HER2 receptor) [33,34] or Cetuximab (EGFR receptor) [35,36], among others, endowing them with great ability for targeting different types of tumoral cells.”
BackgroundTargeted delivery of nano-radiosensitizers for tumor radiotherapy
Shi, S., Zhong, H., Zhang, Y., & Mei, Q. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216101 · Cited by 45
The Rational Design and Biological Mechanisms of Nanoradiosensitizers
Sun, H., Wang, X., & Zhai, S. (2020) · Nanomaterials · doi:10.3390/nano10030504 · Cited by 41
Zhuang, J., Zhou, L., Tang, W., Ma, T., Li, H., Wang, X., Chen, C., & Wang, P. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.111361 · Cited by 31
Nanotechnology enabled radioprotectants to reduce space radiation‐induced reactive oxidative species
Babu, B., Pawar, S., Mittal, A., Kolanthai, E., Neal, C. J., Coathup, M. J., & Seal, S. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1896 · Cited by 26
Approaches for reducing chemo/radiation-induced cardiotoxicity by nanoparticles
Li, K., Chen, W., Ma, L., Yan, L., & Wang, B. (2023) · Environmental Research · doi:10.1016/j.envres.2023.117264 · Cited by 19
Advances in Ultrasmall Inorganic Nanoparticles for Nanomedicine: From Diagnosis to Therapeutics
Oh, J. Y., Villaseñor, K. E., Kian, A. C., & Cormode, D. P. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c02810 · Cited by 16
Inorganic Nanoparticles as Radiosensitizers for Cancer Treatment
Babu, B., Stoltz, S., Mittal, A., Pawar, S., Kolanthai, E., Coathup, M. J., & Seal, S. (2023) · Nanomaterials · doi:10.3390/nano13212873 · Cited by 20
Modulating the Radiation Response for Improved Outcomes in Breast Cancer
Pesch, A. M., Pierce, L. J., & Speers, C. W. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00297 · Cited by 15
A Glucose Oxidase-Curcumin Composite Nanoreactor for Multimodal Synergistic Cancer Therapy
Alsamarat, R., & Sunoqrot, S. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c00479 · Cited by 11
Silica nanoparticles as advanced platforms for nucleic acid delivery
Fanárraga, M. L., & García‐Hevia, L. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102921 · Cited by 10
Strategies for the treatment of breast cancer: from classical drugs to mathematical models
Costa, A., & Vale, N. (2021) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2021316 · Cited by 7
Evaluation of efficacy of tumor-specific nanoliposomal radiosensitizer in radiotherapy
Karabuga, M., Erdogan, S., Filikci, K., Hazıroglu, R., Tuncel, M., & Cengiz, M. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104586 · Cited by 6
Panday, A., Dixena, B., Vyas, A., & Jain, A. K. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.169329 · Cited by 6
Differential Radiosensitizing Effect of 50 nm Gold Nanoparticles in Two Cancer Cell Lines
Pérez-Amor, M. Á., Barrios, L., Armengol, G., & Barquinero, J. F. (2022) · Biology · doi:10.3390/biology11081193 · Cited by 7
“[74], silicon oxide nanoparticles coated with polyamidoamine have yielded a significant radiosensitizing effect on SKBR3 cells, due to their overexpression of HER2.”
BackgroundSih, B. T., Ahmed, A. T., Jawad, M., Al‐Hetty, H. R. A. K., Rekha, M. M., Soothwal, P. K., Naidu, K. S., Arya, R., Mustafa, Y. F., & Abosaoda, M. K. (2025) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-025-10010-8 · Cited by 5
“Gold NPs and silica-based NPs have shown promise in breast cancer radiosensitization [72, 73].”
He, J., Ouyang, S., Chen, X., & Xie, C. (2025) · Advanced NanoBiomed Research · doi:10.1002/anbr.202500084 · Cited by 3
Al-Abdulhadi, S., Majeed, A. A., Polatova, D., Suliman, M., PadmaPriya, G., Karthikeyan, J., Arora, V., Nayak, P. P., Al‐Rashidi, R. R., & Kadhum, W. R. (2026) · Biotechnology Journal · doi:10.1002/biot.70242 · Cited by 1
Chemoresponsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Cancer Therapy
Colilla, M., & Vallet‐Regí, M. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839166136-00451 · Cited by 1
Lunca, S., Morarasu, S., & Dimofte, G. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146522 · Cited by 2
“Many nanoplatforms incorporated targeting ligands, therapeutic payloads, and microenvironment-responsive components [16,17,26,27,45,49,51–53].”
InfluentialNanoradiosensitzers: Preparation, Characterization and Their Performance
Anwar, H., Abbas, B., Khalid, M., Yunas, K., Nosrati, H., Danafar, H., & Sharma, S. K. (2022) · Nanomedicine and nanotoxicology · doi:10.1007/978-3-031-04071-9_4 · Cited by 1
Amorphous silica nanoparticles exhibit antitumor activity in triple‐negative breast cancer cells
Ibarra, A., Ferronato, M. J., Clemente, V., Barrientos, A. B., Alonso, E. N., Fermento, M. E., Coló, G. P., Facchinetti, M. M., Curino, A. C., & Agotegaray, M. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400316
Nano-radiosensitisers and chronoradiotherapy: emerging strategies for precision cancer treatment
Putta, C. L., Pothal, P., Bhatnagar, A., Dey, S., Ramesh, S. S. R., Prabusankar, G., Ray, S., Gamper, A. M., & Rengan, A. K. (2026) · RSC Pharmaceutics · doi:10.1039/d5pm00365b
Metadata
- Authors
- Yamaguchi, H., Hayama, K., Sasagawa, I., Okada, Y., Kawase, T., Tsubokawa, N., & Tsuchimochi, M.
- Affiliations
- Nippon Dental University (JP)
- Niigata University (JP)
- Corresponding author
- Tsuchimochi, Makoto
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-03-19
- Volume
- 19
- Issue
- 3
- Pages
- 908
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5877769
- OpenAlex
- W2790863426
- Cited by
- 30
- References
- 43
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 4 · 2019: 1
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Japan Society for the Promotion of Science (23592783, 15K11303)
- Topics
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- HER2, silica nanoparticles, radiosensitization, breast cancer, PAMAM, antibody-conjugated nanoparticles, targeted drug delivery, SK-BR-3 cells, apoptosis, X-rays, fluorescent dye labeling, nanoparticle uptake
- MeSH terms
- Breast Neoplasms, Cell Nucleus, Cell Survival, Female, Fluorescence, Humans, Lysosomes, Particle Size, Polyamines, Radiation Tolerance, Silicon Dioxide, Erb-b2 Receptor Tyrosine Kinases, Cell Line, Tumor, Cell Proliferation, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.